Close Menu

Diaceutics

Peter Kim, former Merck Research Laboratories president, will return to his alma mater Stanford University as a professor of biochemistry at the School of Medicine.

Diaceutics, CAHG Launch Personalized Rx-Focused Marketing, Educational Firm Bioceutics

Labceutics and Asuragen announced this week that that they will conduct an international, multi-center quality assurance study to track standardization across labs conducting BCR-ABL1 testing on the International Scale.

Amgen said this week that its $415 million proposed acquisition of Icelandic genetics research firm Decode will bolster its ability to evaluate which molecules to advance through its pipeline.

When inking companion diagnostic deals with drug developers, most test makers are trying to get beyond fee-for-service arrangements and strike more creative agreements with potential for bigger profits over a longer period of time.

FDA Approves Phase I Study Design for Cellceutix's Anti-Cancer Drug Kevetrin

By Turna Ray
Pharma may be increasingly investing in personalized medicine, but so far such molecularly-targeted treatments comprise a small slice of the industry's marketed products and revenues.

This article has been updated from a previous version to include information on the filing status of lumiracoxib in Europe, to clarify the current indication for nilotinib, and to correct information about the company's BCR-ABL development partners.

Pages

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.